Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 16;60(2):e0155021.
doi: 10.1128/JCM.01550-21. Epub 2021 Dec 1.

Improved Diagnosis of Viable Parenchymal Neurocysticercosis by Combining Antibody Banding Patterns on Enzyme-Linked Immunoelectrotransfer Blot (EITB) with Antigen Enzyme-Linked Immunosorbent Assay (ELISA)

Affiliations

Improved Diagnosis of Viable Parenchymal Neurocysticercosis by Combining Antibody Banding Patterns on Enzyme-Linked Immunoelectrotransfer Blot (EITB) with Antigen Enzyme-Linked Immunosorbent Assay (ELISA)

Gianfranco Arroyo et al. J Clin Microbiol. .

Abstract

The diagnosis of neurocysticercosis (NCC) depends on neuroimaging and serological confirmation. While antibody detection by enzyme-linked immunoelectrotransfer blot (EITB) fails to predict viable NCC, EITB banding patterns provide information about the host's infection course. Adding antigen enzyme-linked immunosorbent assay (Ag-ELISA) results to EITB banding patterns may improve their ability to predict or rule out of viable NCC. We assessed whether combining EITB banding patterns with Ag-ELISA improves discrimination of viable infection in imaging-confirmed parenchymal NCC. EITB banding patterns were grouped into classes using latent class analysis. True-positive and false-negative Ag-ELISA results in each class were compared using Fisher's exact test. Four classes were identified: 1, EITB negative or positive to GP50 alone (GP50 antigen family); 2, positive to GP42-39 and GP24 (T24/42 family), with or without GP50; and 3 and 4, positive to GP50, GP42-39, and GP24 and reacting to bands in the 8-kDa family. Most cases in classes 3 and 4 had viable NCC (82% and 88%, respectively) compared to classes 2 and 1 (53% and 5%, respectively). Adding positive Ag-ELISA results to class 2 predicted all viable NCC cases (22/22 [100%]), whereas 11/40 patients (27.5%) Ag-ELISA negative had viable NCC (P < 0.001). Only 1/4 patients (25%) Ag-ELISA positive in class 1 had viable NCC, whereas 1/36 patients (2.8%) Ag-ELISA negative had viable NCC (P = 0.192). In classes 3 and 4, adding Ag-ELISA was not contributory. Combining Ag-ELISA with EITB banding patterns improves discrimination of viable from nonviable NCC, particularly for class 2 responses. Together, these complement neuroimaging more appropriately for the diagnosis of viable NCC.

Keywords: Ag-ELISA; EITB banding patterns; Taenia solium; viable NCC.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIG 1
FIG 1
Flowchart of study population selection. RM, magnetic resonance.
FIG 2
FIG 2
Neuroimages showing the characteristics of CNS cyst infection in a patient with parenchymal NCC. (A and B) Black arrows indicate viable cysts visualized using brain magnetic resonance imaging (MRI). (C and D) White arrows indicate calcified lesions on a computed tomography (CT) scan.
FIG 3
FIG 3
Distribution of EITB banding patterns according to class membership. Classes: 1, EITB negative or only positive to antigens of the GP50 family (0 to 1 reactive band); 2, positive to antigens of the T24/42 family, with or without reaction to GP50 antigens (2 to 3 reactive bands); 3, positive to antigens of the GP50 and T24/42 families and positive to antigens of the 8-kDa family (4 to 6 reactive bands); 4, positive to antigens of the GP50 and T24/42 families and strongly positive to antigens of the 8-kDa family (5 to 7 reactive bands).

Similar articles

Cited by

References

    1. Coyle CM, Mahanty S, Zunt JR, Wallin MT, Cantey PT, White AC, Jr, O'Neal SE, Serpa JA, Southern PM, Wilkins P, McCarthy AE, Higgs ES, Nash TE. 2012. Neurocysticercosis: neglected but not forgotten. PLoS Negl Trop Dis 6:e1500. 10.1371/journal.pntd.0001500. - DOI - PMC - PubMed
    1. Garcia HH, Nash TE, Del Brutto OH. 2014. Clinical symptoms, diagnosis, and treatment of neurocysticercosis. Lancet Neurol 13:1202–1215. 10.1016/S1474-4422(14)70094-8. - DOI - PMC - PubMed
    1. Lightowlers MW, Donadeu M. 2017. Designing a minimal intervention strategy to control Taenia solium. Trends Parasitol 33:426–434. 10.1016/j.pt.2017.01.011. - DOI - PubMed
    1. Garcia HH, Cysticercosis Working Group in Peru. 2012. Neurocysticercosis in immigrant populations. J Travel Med 19:73–75. 10.1111/j.1708-8305.2011.00583.x. - DOI - PMC - PubMed
    1. O'Neal SE, Flecker RH. 2015. Hospitalization frequency and charges for neurocysticercosis, United States, 2003–2012. Emerg Infect Dis 21:969–976. 10.3201/eid2106.141324. - DOI - PMC - PubMed

Publication types